Trial Type
First-Line-Therapy (Metastatic Disease/Hematology)
Description for experts
A phase 3 trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab versus Pembrolizumab in patients with repviously untreated unresectable locally advanced or metastatic melanoma.
Description for laymen
JSON Data
{
"short_title": "Harmony (R3767-ONC-2011)",
"data_mode": "900",
"data_mode_number": "000002303",
"official_title": "A phase 3 trial of Fianlimab 8REgn3767, Anti-Lag-3) + Cemiplimab versus Pemprolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma",
"accrual_state": "running",
"therapeutic_value": "therapeutic",
"therapieansatz_value": "palliativ",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "first",
"ctgov_number": null,
"eudract_number": "2021-004453-23",
"general_contact_email": "oncostudien.dermatologie@ukdd.de",
"general_contact_phone": "+49 351-45819782",
"hauptpruefer_dd_name": "Prof. Dr. med. Friedegund Meier",
"description_laie_de": "Phase-III-Studie zu Fianlimab (REGN3767, Anti-LAG-3-Antik\u00f6rper) plus Cemiplimab versus Pembrolizumab bei Patienten mit zuvor unbehandeltem \r\nirresektablem lokal fortgeschrittenem oder metastasiertem Melanom.",
"description_laie_en": null,
"description_expert_de": null,
"description_expert_en": "A phase 3 trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab versus Pembrolizumab in patients with repviously untreated unresectable locally advanced or metastatic melanoma.",
"rechtsgrundlage_value": "AMG",
"phase_amg_value": "III",
"main_cat_id": 5,
"sub_cat_id": 35
}
